The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators - PubMed (original) (raw)
. 2001 Sep 21;276(38):35684-92.
doi: 10.1074/jbc.M101097200. Epub 2001 Jul 25.
Affiliations
- PMID: 11473106
- DOI: 10.1074/jbc.M101097200
Free article
The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators
A L Wijayaratne et al. J Biol Chem. 2001.
Free article
Abstract
The human estrogen receptor alpha-isoform (ERalpha) is a nuclear transcription factor that displays a complex pharmacology. In addition to classical agonists and antagonists, the transcriptional activity of ERalpha can be regulated by selective estrogen receptor modulators, a new class of drugs whose relative agonist/antagonist activity is determined by cell context. It has been demonstrated that the binding of different ligands to ERalpha results in the formation of unique ERalpha-ligand conformations. These conformations have been shown to influence ERalpha-cofactor binding and, therefore, have a profound impact on ERalpha pharmacology. In this study, we demonstrate that the nature of the bound ligand also influences the stability of ERalpha, revealing an additional mechanism by which the pharmacological activity of a compound is determined. Of note we found that although all ERalpha-ligand complexes can be ubiquitinated and degraded by the 26 S proteasome in vivo, the mechanisms by which they are targeted for proteolysis appear to be different. Specifically, for agonist-activated ERalpha, an inverse relationship between transcriptional activity and receptor stability was observed. This relationship does not extend to selective estrogen receptor modulators and pure antagonists. Instead, it appears that with these compounds, the determinant of receptor stability is the ligand-induced conformation of ERalpha. We conclude that the different conformational states adopted by ERalpha in the presence of different ligands influence transcriptional activity directly by regulating cofactor binding and indirectly by modulating receptor stability.
Similar articles
- Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.
Katzenellenbogen BS, Choi I, Delage-Mourroux R, Ediger TR, Martini PG, Montano M, Sun J, Weis K, Katzenellenbogen JA. Katzenellenbogen BS, et al. J Steroid Biochem Mol Biol. 2000 Nov 30;74(5):279-85. doi: 10.1016/s0960-0760(00)00104-7. J Steroid Biochem Mol Biol. 2000. PMID: 11162936 Review. - Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists.
Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J, Nilsson S. Barkhem T, et al. Mol Pharmacol. 1998 Jul;54(1):105-12. doi: 10.1124/mol.54.1.105. Mol Pharmacol. 1998. PMID: 9658195 - Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells.
Liu H, Park WC, Bentrem DJ, McKian KP, Reyes Ade L, Loweth JA, Schafer JM, Zapf JW, Jordan VC. Liu H, et al. J Biol Chem. 2002 Mar 15;277(11):9189-98. doi: 10.1074/jbc.M108335200. Epub 2001 Dec 20. J Biol Chem. 2002. PMID: 11751902 Free PMC article. - Protein kinase A activation of estrogen receptor alpha transcription does not require proteasome activity and protects the receptor from ligand-mediated degradation.
Tsai HW, Katzenellenbogen JA, Katzenellenbogen BS, Shupnik MA. Tsai HW, et al. Endocrinology. 2004 Jun;145(6):2730-8. doi: 10.1210/en.2003-1470. Epub 2004 Mar 19. Endocrinology. 2004. PMID: 15033909
Cited by
- Antiestrogens: structure-activity relationships and use in breast cancer treatment.
Traboulsi T, El Ezzy M, Gleason JL, Mader S. Traboulsi T, et al. J Mol Endocrinol. 2017 Jan;58(1):R15-R31. doi: 10.1530/JME-16-0024. Epub 2016 Oct 11. J Mol Endocrinol. 2017. PMID: 27729460 Free PMC article. Review. - From Pure Antagonists to Pure Degraders of the Estrogen Receptor: Evolving Strategies for the Same Target.
Mottamal M, Kang B, Peng X, Wang G. Mottamal M, et al. ACS Omega. 2021 Mar 30;6(14):9334-9343. doi: 10.1021/acsomega.0c06362. eCollection 2021 Apr 13. ACS Omega. 2021. PMID: 33869913 Free PMC article. Review. - Proposal for a role of the Hsp90/Hsp70-based chaperone machinery in making triage decisions when proteins undergo oxidative and toxic damage.
Pratt WB, Morishima Y, Peng HM, Osawa Y. Pratt WB, et al. Exp Biol Med (Maywood). 2010 Mar;235(3):278-89. doi: 10.1258/ebm.2009.009250. Exp Biol Med (Maywood). 2010. PMID: 20404045 Free PMC article. Review. - Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells.
De Amicis F, Thirugnansampanthan J, Cui Y, Selever J, Beyer A, Parra I, Weigel NL, Herynk MH, Tsimelzon A, Lewis MT, Chamness GC, Hilsenbeck SG, Andò S, Fuqua SA. De Amicis F, et al. Breast Cancer Res Treat. 2010 May;121(1):1-11. doi: 10.1007/s10549-009-0436-8. Epub 2009 Jun 17. Breast Cancer Res Treat. 2010. PMID: 19533338 Free PMC article. - Estrogen downregulates the proximal tubule type IIa sodium phosphate cotransporter causing phosphate wasting and hypophosphatemia.
Faroqui S, Levi M, Soleimani M, Amlal H. Faroqui S, et al. Kidney Int. 2008 May;73(10):1141-50. doi: 10.1038/ki.2008.33. Epub 2008 Feb 27. Kidney Int. 2008. PMID: 18305465 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources